Liquidia First Quarter 2025 Earnings: Misses Expectations
Scotiabank Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $36
Raymond James Maintains Liquidia(LQDA.US) With Buy Rating, Raises Target Price to $29
LifeSci Capital Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $35
Raymond James Maintains Strong Buy on Liquidia, Raises Price Target to $29
Liquidia Analyst Ratings
Wells Fargo Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $20
Needham Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $25
Liquidia Corp (LQDA) Q1 2025 Earnings Call Highlights: Strategic Advances and Legal Wins Propel ...
Analysts' Opinions Are Mixed on These Healthcare Stocks: Arcellx Inc (ACLX), Vir Biotechnology (VIR) and Liquidia Technologies (LQDA)
Favorable Court Decision and Market Potential Propel Liquidia Technologies' Buy Rating
Buckley Capital's Views on Liquidia Corp. (LQDA)
Liquidia | 10-Q: Q1 2025 Earnings Report
Liquidia Corporation Provides Corporate Update and Financial Results Ahead of May 24 FDA Decision on YUTREPIA NDA
Liquidia | 8-K: Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update
Liquidia GAAP EPS of -$0.45 Misses by $0.05, Revenue of $3.12M Misses by $0.11M
Earnings Flash (LQDA) LIQUIDIA CORPORATION Reports Q1 Revenue $3.1M, Vs. FactSet Est of $3.3M
Liquidia 1Q Loss/Shr 45c >LQDA
Press Release: Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update
Liquidia Technologies Updates Audit Report for March 2025